D STATES PATENT AND TRADEMARK

In re Patent Application of

Attv Dkt. 2752-15

C# M#

1633

MAERTENS et al.

Serial No. 09/638,693

Examiner: Martinell

August 15, 200 Filed:

Date: January 17, 2002

Group Art Unit:

Title:

NEW SEQUENCES OF HERASINS C VIRUS GENOTYPES AND THEIR USE AS THERAPEUTIC AND DIAGNOSTIC AGENTS

Assistant Commissioner for Patents

Washington, DC 20231

Sir:

RESPONSE/AMENDMENT/LETTER

TON CHILLIAN STONE This is a response/amendment/letter in the above-identified application and includes an attachment which is hereby incorporated by reference and the signature below serves as the signature to the attachment in the absence of any other signature thereon.

Fees are attached as calculated below:

Total effective claims after amendment 0 minus highest number previously paid for 20 (at least 20) = 0 x \$ 18.00	\$	0.00
Independent claims after amendment 0 minus highest number previously paid for 3 (at least 3) = 0 x \$ 84.00	\$	0.00
If proper multiple dependent claims now added for first time, add \$280.00 (ignore improper)	\$	0.00
Petition is hereby made to extend the current due date so as to cover the filing date of this paper and attachment(s) (\$110.00/1 month; \$400.00/2 months; \$920.00/3 months)	\$	0.00
Terminal disclaimer enclosed, add \$ 110.00	\$	0.00
☐ First/second submission after Final Rejection pursuant to 37 CFR 1.129(a) (\$740.00) ☐ Please enter the previously unentered , filed ☐ Submission attached	\$	0.00
Subtotal .	\$	0.00
If "small entity," then enter half (1/2) of subtotal and subtract Applicant claims "small entity" status. Statement filed herewith	-\$	0.00
Rule 56 Information Disclosure Statement Filing Fee (\$180.00)	\$	0.00
Assignment Recording Fee (\$40.00)	\$	0.00
Other:		0.00
TOTAL FEE ENCLOSED	\$	0.00

The Commissioner is hereby authorized to charge any deficiency, or credit any overpayment, in the fee(s) filed, or asserted to be filed, or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Account No. 14-1140. A duplicate copy of this sheet is attached.

1100 North Glebe Road, 8th Floor Arlington, Virginia 22201-4714 Telephone: (703) 816-4000 Facsimile: (703) 816-4100

BJS:eaw

Signature:

NIXON & VANDERHYE P.C.

By Atty: B. J. Sadoff, Reg. No. 36,663

N THE UNU ED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

MAERTENS et al.

Attv. Ref.:

2752-15

Serial No.

09/638,693

Group:

1633

Filed:

August 15, 2000

Examiner:

Martinell

For:

NEW SEQUENCES OF HEPATITIS C VIRUS

GENOTYPES AND THEIR USE AS THERAPEUTIC AND

DIAGNOSTIC AGENTS

January 17, 2002

Assistant Commissioner for Patents Washington, DC 20231

Sir:

RESPONSE

Responsive to the Official Action dated December 17, 2001, the applicants elect, with traverse, SEQ ID NO:62 of claim 69, for further prosecution in the above.

Reconsideration and withdrawal of the restriction requirement is requested as the Examiner has failed to indicate, pursuant to MPEP, rules or law, how the alleged separately patentable sequences define separate inventions. The Examiner's apparent reliance on a *per se* rule of individual sequences being separately patentable inventions is, with all due respect, submitted to be improper. Reconsideration and withdrawal of the restriction requirement are requested. At a minimum, the Examiner is requested to provide a basis for the restriction requirement.

The Examiner indicates the claims have been renumbered as the Examiner believes only 21 claims were originally filed. The applicants note however that the originally filed application contained 23 claims, as noted on the Filing Receipt mailed

MAERTENS et al. Serial No. 09/638,693

October 12, 2000 as well on pages 93 and 94 of the originally filed application which contains part of claim 21, claim 22, and claim 23. Accordingly, the applicants' numbering of the new claims 24-55 in the Amendment filed November 14, 2000, and the subsequent submission of claims 56-85 in the Preliminary Amendment of May 17, 2001, are submitted to be proper. The applicants submit therefore that claims 56-85 are pending. Clarification of the Examiner's remarks are requested in the event the Examiner continues to believe the claims should be renumbered.

Reconsideration and withdrawal of the restriction requirement are requested along with an early and favorable Action on the merits of all the claimed subject matter.

Respectfully submitted,

NIXON & VANDERHYE P.C.

By:

B. J. Sadoff Reg. No. 36,663

BJS:eaw

1100 North Glebe Road, 8th Floor Arlington, VA 22201-4714

Telephone: (703) 816-4000

Facsimile: (703) 816-4100